Abdul Moiz Hafiz, MD
Play Button

Abdul Moiz Hafiz, MD

Structural Heart Disease Specialist
Cardiology, Internal Medicine | Cardiology | Interventional Cardiology
Accepting new patients
Call for an appointment
217-545-8000
or
Request appointment
Languages:
English, Urdu, Kashmiri, Hindi

    About me

    Structural Heart Disease Conditions Dr. Hafiz focuses on:

    • TAVR
    • MitraClip
    • PFO closure
    • ASD closure
    • Watchman Device

    Gender

    Male

    Additional languages spoken

    Urdu,
    Kashmiri,
    Hindi

    Education & training

    Positions
    Assistant Professor
    Medical School
    Government Medical College Srinagar, University of Kashmir, Jammu and Kashmir, India
    Residency
    Winthrop University Hospital, Stony Brook University School Of Medicine, Mineola, NY - Internal Medicine
    Fellowship
    Cardiovascular Medicine Fellow: Winthrop University Hospital, Stony Brook University School Of Medicine, Mineola, NY
    Cardiovascular and Research Fellow in Interventional Cardiology: Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
    Advanced Structural Heart Disease Fellow: University of Massachusetts Medical School, Worcester, MA

    Specialties

    Conditions

    Treatments & procedures

    Patients in waiting room

    Appointments

    SIU Medicine strongly encourages all patients to verify coverage, benefits and which providers are considered in-network with their health plan. SIU Medicine has more than 300 health care providers ready to serve you and your family. SIU Medicine accepts a wide variety of governmental and non-governmental health plans to serve our community. 

    Clinical locations

    Locations

    SIU Medicine Heart and Vascular Center | Springfield

    747 N. Rutledge Street Springfield, IL 62702 4th Floor
    Get Directions
    Mon - Fri: 8:00 am-4:30 pm
    217-545-8000

    Hospital privileges

    • Memorial Health, Springfield IL

    Clinical trials

    Trial
    Internal Medicine

    COSIRA-II

    Active recruiting
    To demonstrate the safety and effectiveness of the Shockwave Reducer for treatment of patients with refractory angina pectoris treated with maximally tolerated guideline-directed medical therapy who demonstrate objective evidence of reversible myocardial ischemia in the distribution of the left coronary artery and who are deemed unsuitable for revascularization.
    Contact: Madison Hollinshead 217-545-9738
    Trial
    Internal Medicine

    COSIRA-II

    Active recruiting
    To demonstrate the safety and effectiveness of the Shockwave Reducer for treatment of patients with refractory angina pectoris treated with maximally tolerated guideline-directed medical therapy who demonstrate objective evidence of reversible myocardial ischemia in the distribution of the left coronary artery and who are deemed unsuitable for revascularization.
    Contact: Madison Hollinshead 217-545-9738
    Trial
    Cardiology

    STEMI DTU

    Active not recruiting
    The purpose of this clinical trial is to demonstrate the safety and effectiveness of primary left ventricular (LV) unloading and a 30-minute delay-to-reperfusion versus current standard of care in reducing infarct size and heart failure-related clinical events in patients presenting with anterior ST-elevation myocardial infarction (STEMI).
    Contact: Kathlena Mottershaw 217-545-7387
    Trial
    Cardiology

    STEMI DTU

    Active not recruiting
    The purpose of this clinical trial is to demonstrate the safety and effectiveness of primary left ventricular (LV) unloading and a 30-minute delay-to-reperfusion versus current standard of care in reducing infarct size and heart failure-related clinical events in patients presenting with anterior ST-elevation myocardial infarction (STEMI).
    Contact: Kathlena Mottershaw 217-545-7387
    Trial
    Internal Medicine

    RECHARGE

    Active recruiting

    Trial Objective: To compare the long-term effects of percutaneous coronary intervention (PCI) (i.e., stenting) versus coronary artery bypass grafting (CABG) (i.e., open-heart surgery) in women and minorities.

    You may be eligible to participate if you:

    • Are a woman and/or are Black or Hispanic
    • And planning to receive a heart stent (PCI) or open-heart surgery (CABG) to treat blocked arteries
    Contact: Katie Mottershaw 217-545-7387
    Trial
    Internal Medicine

    RECHARGE

    Active recruiting

    Trial Objective: To compare the long-term effects of percutaneous coronary intervention (PCI) (i.e., stenting) versus coronary artery bypass grafting (CABG) (i.e., open-heart surgery) in women and minorities.

    You may be eligible to participate if you:

    • Are a woman and/or are Black or Hispanic
    • And planning to receive a heart stent (PCI) or open-heart surgery (CABG) to treat blocked arteries
    Contact: Katie Mottershaw 217-545-7387
    Trial
    Internal Medicine

    PE-TRACT

    Active recruiting
    The study is designed to identify the best way to treat pulmonary embolism- with blood thinners alone or blood thinners with catheter directed therapy.
    Contact: Katie Mottershaw 217-545-7387
    Trial
    Internal Medicine

    PE-TRACT

    Active recruiting
    The study is designed to identify the best way to treat pulmonary embolism- with blood thinners alone or blood thinners with catheter directed therapy.
    Contact: Katie Mottershaw 217-545-7387
    Trial
    Internal Medicine

    VICTORION-2 PREVENT

    Active not recruiting
    PURPOSE: The purpose of this clinical trial is to find out if the investigational study treatment, called inclisiran, can help prevent cardiovascular events (such as heart attacks, strokes, and cardiovascular-related deaths) in adults who already have been diagnosed with cardiovascular disease.
    Contact: Katie Mottershaw 217-545-7387
    Trial
    Internal Medicine

    VICTORION-2 PREVENT

    Active not recruiting
    PURPOSE: The purpose of this clinical trial is to find out if the investigational study treatment, called inclisiran, can help prevent cardiovascular events (such as heart attacks, strokes, and cardiovascular-related deaths) in adults who already have been diagnosed with cardiovascular disease.
    Contact: Katie Mottershaw 217-545-7387
    Trial
    Internal Medicine

    RADIANCE Continued Access Protocol (CAP): A study of the ReCor Medical Paradise System in Clinical Hypertension

    Active not recruiting
    The purpose of this clinical trial is to find out if a medical device called the Paradise Renal Denervation System can lower blood pressure in patients who have hypertension.
    Contact: Katy Martz 217-545-4342

    Related articles

    Scope editors

    SIU Medicine community shares artistry in 2025 Scope

    SIU School of Medicine unveiled the 2025 edition of SCOPE, its student-produced literary magazine, at an awards reception April 21. The booklet contains short stories, poems and artwork from students